{'fraction_non_alphanumeric': 0.032948929159802305, 'fraction_numerical': 0.0032948929159802307, 'mean_word_length': 5.608695652173913, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Androgen receptor or estrogen receptor‐β blockade alters DHEA‐, DHT‐, and E2‐induced proliferation and PSA production in human prostate cancer cells

Dehydroepiandrosterone (DHEA) is an endogenous steroid that is metabolized to androgens and/or estrogens in the human prostate. DHEA levels decline with age, and use of DHEA supplements to retard the aging process is of unproved effectiveness and safety. LNCaP and LAPC‐4 prostate cancer cells were used to determine whether DHEA‐modulated proliferation and prostate specific antigen (PSA) production were mediated via the androgen receptor (AR) and/or ERβ.